Ticker brief
AIM AIM IMMUNOTECH INC
Consumer, Non-cyclical · Biotechnology
last close
$0.2800
1 day
-5.4%
14 days
-26.3%
mkt cap
·
signals 14d
5
authors 14d
1
Sentiment — last 14 days
daily mean sentiment, 2026-06-24 → 2026-06-25 · now +0.10 (−1 bearish … +1 bullish)
Who spoke1
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @OzmosiHealth | C | · | 5 | +0.13 |
Recent signals5of 5 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-06-25 | @OzmosiHealth | +0.10 | AIM announces timing for P2 pancreatic cancer results in 2Q27 for Rintatolimod. | -21.2% | tweet ↗ |
| 2026-06-25 | @OzmosiHealth | +0.10 | AIM announces timing for P2 pancreatic cancer results in 2Q27 for Durvalumab. | -21.2% | tweet ↗ |
| 2026-06-25 | @OzmosiHealth | +0.10 | AIM announces timing for P2 pancreatic cancer results in 1Q27 for Durvalumab. | -21.2% | tweet ↗ |
| 2026-06-25 | @OzmosiHealth | +0.10 | AIM announces timing for P2 pancreatic cancer results in 1Q27 for Rintatolimod. | -21.2% | tweet ↗ |
| 2026-06-24 | @OzmosiHealth | +0.25 | AIM ImmunoTech says Ampligen continues through pancreatic cancer clinical milestones. | -25.1% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.